Skip to main content
SpringerLink
Log in

Malignant Liver Lesions

Liver Disorders: A Point-of-Care Clinical Guide

  • Chapter
  • First Online:
Liver Disorders

  • 1589 Accesses

Abstract

The management of malignant liver lesions is complex and requires a multidisciplinary approach. Coexisting liver dysfunction and cirrhosis are common, increase the risk of toxicity with cancer therapy, and confer a risk of liver failure and mortality that are independent of the cancer itself. Liver cancer prognosis is therefore determined not only by the extent of the cancer but also by the severity of underlying liver dysfunction. Treatments for liver cancer include potentially curative therapies such as surgical resection, liver transplantation, and percutaneous ablation, as well as palliative therapies such as transarterial chemoembolization, transarterial radioembolization, radiation therapy, and systemic chemotherapy. This chapter summarizes the epidemiology, risk factors, and approach to the diagnosis and management of malignant liver lesions.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 199.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Abbreviations

AFP:

Alpha-fetoprotein

BCLC:

Barcelona clinic liver cancer

CCA:

Cholangiocarcinoma

CEA:

Carcinoembryonic antigen

CT:

Computerized tomography

EHE:

Epithelioid hemangioendothelioma

HB:

Hepatoblastoma

HBV:

Hepatitis B

HCC:

Hepatocellular carcinoma

HCV:

Hepatitis C

HIV:

Human immunodeficiency virus

HSTCL:

Hepatosplenic T-cell lymphoma

MRI:

Magnetic resonance imaging

References

  1. American Cancer Society. Cancer facts and figures. http://seer.cancer.gov/statfacts/html/livibd.html. Accessed 3 Feb 2015.

  2. Marrero JA, Ahn J, Rajender Reddy K, American College of Gastroenterology. ACG clinical guideline: the diagnosis and management of focal liver lesions. Am J Gastroenterol. 2014;109(9):1328–47. quiz 1348.

    Article  PubMed  Google Scholar 

  3. Goodman ZD. Neoplasms of the liver. Mod Pathol. 2007;20 Suppl 1:S49–60.

    Article  PubMed  Google Scholar 

  4. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC Cancer Base No. 11. http://globocan.iarc.fr. Accessed 16 Feb 2015.

  5. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology. 2004;127(5 Suppl 1):S35–50.

    Article  PubMed  Google Scholar 

  6. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365(12):1118–27.

    Article  CAS  PubMed  Google Scholar 

  7. Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53(3):1020–2.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Stoot JH, Coelen RJ, De Jong MC, Dejong CH. Malignant transformation of hepatocellular adenomas into hepatocellular carcinomas: a systematic review including more than 1600 adenoma cases. HPB (Oxford). 2010;12(8):509–22.

    Article  Google Scholar 

  9. Donato F, Tagger A, Gelatti U, Parrinello G, Boffetta P, Albertini A, et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol. 2002;155(4):323–31.

    Article  CAS  PubMed  Google Scholar 

  10. Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis. 1999;19(3):271–85.

    Article  CAS  PubMed  Google Scholar 

  11. Yang HI, Sherman M, Su J, Chen PJ, Liaw YF, Iloeje UH, et al. Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Clin Oncol. 2010;28(14):2437–44.

    Article  PubMed  Google Scholar 

  12. Yuen MF, Tanaka Y, Fong DY, Fung J, Wong DK, Yuen JC, et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol. 2009;50(1):80–8.

    Article  PubMed  Google Scholar 

  13. Shih WL, Chang HC, Liaw YF, Lin SM, Lee SD, Chen PJ, et al. Influences of tobacco and alcohol use on hepatocellular carcinoma survival. Int J Cancer. 2012;131(11):2612–21.

    Article  CAS  PubMed  Google Scholar 

  14. Marrero JA, Fontana RJ, Fu S, Conjeevaram HS, Su GL, Lok AS. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol. 2005;​42(2):218–24.

    Article  CAS  PubMed  Google Scholar 

  15. Sang LX, Chang B, Li XH, Jiang M. Consumption of coffee associated with reduced risk of liver cancer: a meta-analysis. BMC Gastroenterol. 2013;13:34-230X-13-34.

    Google Scholar 

  16. Silva MA, Hegab B, Hyde C, Guo B, Buckels JA, Mirza DF. Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut. 2008;57(11):1592–6.

    Article  CAS  PubMed  Google Scholar 

  17. Livraghi T, Goldberg SN, Lazzaroni S, Meloni F, Solbiati L, Gazelle GS. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology. 1999;210(3):655–61.

    Article  CAS  PubMed  Google Scholar 

  18. Lencioni RA, Allgaier HP, Cioni D, Olschewski M, Deibert P, Crocetti L, et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology. 2003;228(1):235–40.

    Article  PubMed  Google Scholar 

  19. Llovet JM, Vilana R, Bru C, Bianchi L, Salmeron JM, Boix L, et al. Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology. 2001;33(5):1124–9.

    Article  CAS  PubMed  Google Scholar 

  20. Livraghi T, Solbiati L, Meloni MF, Gazelle GS, Halpern EF, Goldberg SN. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology. 2003;226(2):441–51.

    Article  PubMed  Google Scholar 

  21. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334(11):693–9.

    Article  CAS  PubMed  Google Scholar 

  22. Patel SS, Arrington AK, McKenzie S, Mailey B, Ding M, Lee W, et al. Milan criteria and UCSF criteria: a preliminary comparative study of liver transplantation outcomes in the United States. Int J Hepatol. 2012;2012:253517.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Yao FY, Ferrell L, Bass NM, Bacchetti P, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl. 2002;8(9):765–74.

    Article  PubMed  Google Scholar 

  24. Yao FY, Bass NM, Nikolai B, Davern TJ, Kerlan R, Wu V, et al. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl. 2002;8(10):873–83.

    Article  PubMed  Google Scholar 

  25. Ioannou GN, Perkins JD, Carithers Jr RL. Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival. Gastroenterology. 2008;134(5):1342–51.

    Article  PubMed  Google Scholar 

  26. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology. 2004;127(5 Suppl 1):S179–88.

    Article  CAS  PubMed  Google Scholar 

  27. Llovet JM, Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology. 2003;37(2):429–42.

    Article  CAS  PubMed  Google Scholar 

  28. Mahnken AH, Spreafico C, Maleux G, Helmberger T, Jakobs TF. Standards of practice in transarterial radioembolization. Cardiovasc Intervent Radiol. 2013;36(3):613–22.

    Article  PubMed  Google Scholar 

  29. Moreno-Luna LE, Yang JD, Sanchez W, Paz-Fumagalli R, Harnois DM, Mettler TA, et al. Efficacy and safety of transarterial radioembolization versus chemoembolization in patients with hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2013;36(3):714–23.

    Article  PubMed  Google Scholar 

  30. Salem R, Gilbertsen M, Butt Z, Memon K, Vouche M, Hickey R, et al. Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin Gastroenterol Hepatol. 2013;11(10):1358–1365.e1.

    Article  PubMed  Google Scholar 

  31. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34.

    Article  CAS  PubMed  Google Scholar 

  32. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90.

    Article  CAS  PubMed  Google Scholar 

  33. El-Serag HB, Davila JA. Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study. Hepatology. 2004;39(3):798–803.

    Article  PubMed  Google Scholar 

  34. Njei B, Konjeti VR, Ditah I. Prognosis of patients with fibrolamellar hepatocellular carcinoma versus conventional hepatocellular carcinoma: a systematic review and meta-analysis. Gastrointest Cancer Res. 2014;7(2):49–54.

    PubMed  PubMed Central  Google Scholar 

  35. Mavros MN, Mayo SC, Hyder O, Pawlik TM. A systematic review: treatment and prognosis of patients with fibrolamellar hepatocellular carcinoma. J Am Coll Surg. 2012;215(6):​820–30.

    Article  PubMed  Google Scholar 

  36. Grossman EJ, Millis JM. Liver transplantation for non-hepatocellular carcinoma malignancy: indications, limitations, and analysis of the current literature. Liver Transpl. 2010;16(8):​930–42.

    Article  PubMed  Google Scholar 

  37. Maddrey WC, Sorrell MF, Schiff ER, Schiff L, Schiff ER. Schiff’s diseases of the liver. Schiff's diseases of the liver 11e; Diseases of the liver 2012.

    Google Scholar 

  38. Razumilava N, Gores GJ, Lindor KD. Cancer surveillance in patients with primary sclerosing cholangitis. Hepatology. 2011;54(5):1842–52.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Rimola J, Forner A, Reig M, Vilana R, de Lope CR, Ayuso C, et al. Cholangiocarcinoma in cirrhosis: absence of contrast washout in delayed phases by magnetic resonance imaging avoids misdiagnosis of hepatocellular carcinoma. Hepatology. 2009;50(3):791–8.

    Article  PubMed  Google Scholar 

  40. Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet. 2005;366(9493):1303–14.

    Article  PubMed  Google Scholar 

  41. Khan SA, Davidson BR, Goldin RD, Heaton N, Karani J, Pereira SP, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update. Gut. 2012;61(12):1657–69.

    Article  CAS  PubMed  Google Scholar 

  42. Blechacz B, Komuta M, Roskams T, Gores GJ. Clinical diagnosis and staging of cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 2011;8(9):512–22.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Rosen CB, Heimbach JK, Gores GJ. Surgery for cholangiocarcinoma: the role of liver transplantation. HPB (Oxford). 2008;10(3):186–9.

    Article  CAS  Google Scholar 

  44. Endo I, Gonen M, Yopp AC, Dalal KM, Zhou Q, Klimstra D, et al. Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg. 2008;248(1):84–96.

    Article  PubMed  Google Scholar 

  45. Rajagopalan V, Daines WP, Grossbard ML, Kozuch P. Gallbladder and biliary tract carcinoma: a comprehensive update, part 1. Oncology (Williston Park). 2004;18(7):889–96.

    Google Scholar 

  46. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Maraveyas A, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–81.

    Article  CAS  PubMed  Google Scholar 

  47. Darwish Murad S, Kim WR, Harnois DM, Douglas DD, Burton J, Kulik LM, et al. Efficacy of neoadjuvant chemoradiation, followed by liver transplantation, for perihilar cholangiocarcinoma at 12 US centers. Gastroenterology. 2012;143(1):88–98.e3. quiz e14.

    Article  PubMed  Google Scholar 

  48. Fletcher CD. The evolving classification of soft tissue tumours—an update based on the new 2013 WHO classification. Histopathology. 2014;64(1):2–11.

    Article  PubMed  Google Scholar 

  49. Mehrabi A, Kashfi A, Fonouni H, Schemmer P, Schmied BM, Hallscheidt P, et al. Primary malignant hepatic epithelioid hemangioendothelioma: a comprehensive review of the literature with emphasis on the surgical therapy. Cancer. 2006;107(9):2108–21.

    Article  PubMed  Google Scholar 

  50. Woodall CE, Scoggins CR, Lewis AM, McMasters KM, Martin RC. Hepatic malignant epithelioid hemangioendothelioma: a case report and review of the literature. Am Surg. 2008;74(1):64–8.

    PubMed  Google Scholar 

  51. Remiszewski P, Szczerba E, Kalinowski P, Gierej B, Dudek K, Grodzicki M, et al. Epithelioid hemangioendothelioma of the liver as a rare indication for liver transplantation. World J Gastroenterol. 2014;20(32):11333–9.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Poggi Machuca L, Ibarra Chirinos O, Lopez Del Aguila J, Villanueva Pflucker M, Camacho Zacarias F, Tagle Arrospide M, et al. Hepatic angiosarcoma: case report and review of literature. Rev Gastroenterol Peru. 2012;32(3):317–22.

    PubMed  Google Scholar 

  53. Zheng YW, Zhang XW, Zhang JL, Hui ZZ, Du WJ, Li RM, et al. Primary hepatic angiosarcoma and potential treatment options. J Gastroenterol Hepatol. 2014;29(5):906–11.

    Article  CAS  PubMed  Google Scholar 

  54. Huang NC, Wann SR, Chang HT, Lin SL, Wang JS, Guo HR. Arsenic, vinyl chloride, viral hepatitis, and hepatic angiosarcoma: a hospital-based study and review of literature in Taiwan. BMC Gastroenterol. 2011;11:142-230X-11-142.

    Google Scholar 

  55. Koyama T, Fletcher JG, Johnson CD, Kuo MS, Notohara K, Burgart LJ. Primary hepatic angiosarcoma: findings at CT and MR imaging. Radiology. 2002;222(3):667–73.

    Article  PubMed  Google Scholar 

  56. Orlando G, Adam R, Mirza D, Soderdahl G, Porte RJ, Paul A, et al. Hepatic hemangiosarcoma: an absolute contraindication to liver transplantation—the European Liver Transplant Registry experience. Transplantation. 2013;95(6):872–7.

    Article  PubMed  Google Scholar 

  57. Maluf D, Cotterell A, Clark B, Stravitz T, Kauffman HM, Fisher RA. Hepatic angiosarcoma and liver transplantation: case report and literature review. Transplant Proc. 2005;37(5):2195–9.

    Article  CAS  PubMed  Google Scholar 

  58. Czauderna P, Lopez-Terrada D, Hiyama E, Haberle B, Malogolowkin MH, Meyers RL. Hepatoblastoma state of the art: pathology, genetics, risk stratification, and chemotherapy. Curr Opin Pediatr. 2014;26(1):19–28.

    Article  CAS  PubMed  Google Scholar 

  59. Zheng MH, Zhang L, Gu DN, Shi HQ, Zeng QQ, Chen YP. Hepatoblastoma in adult: review of the literature. J Clin Med Res. 2009;1(1):13–6.

    PubMed  PubMed Central  Google Scholar 

  60. Otte JB. Progress in the surgical treatment of malignant liver tumors in children. Cancer Treat Rev. 2010;36(4):360–71.

    Article  PubMed  Google Scholar 

  61. Melato M, Laurino L, Mucli E, Valente M, Okuda K. Relationship between cirrhosis, liver cancer, and hepatic metastases. An autopsy study. Cancer. 1989;64(2):455–9.

    Article  CAS  PubMed  Google Scholar 

  62. Johnston FM, Mavros MN, Herman JM, Pawlik TM. Local therapies for hepatic metastases. J Natl Compr Canc Netw. 2013;11(2):153–60.

    Article  PubMed  Google Scholar 

  63. Mayo SC, Pawlik TM. Thermal ablative therapies for secondary hepatic malignancies. Cancer J. 2010;16(2):111–7.

    Article  PubMed  Google Scholar 

  64. Reddy SK, Clary BM. Neuroendocrine liver metastases. Surg Clin North Am. 2010;90(4):853–61.

    Article  PubMed  Google Scholar 

  65. Gedaly R, Daily MF, Davenport D, McHugh PP, Koch A, Angulo P, et al. Liver transplantation for the treatment of liver metastases from neuroendocrine tumors: an analysis of the UNOS database. Arch Surg. 2011;146(8):953–8.

    Article  PubMed  Google Scholar 

  66. Groeschl RT, Nachmany I, Steel JL, Reddy SK, Glazer ES, de Jong MC, et al. Hepatectomy for noncolorectal non-neuroendocrine metastatic cancer: a multi-institutional analysis. J Am Coll Surg. 2012;214(5):769–77.

    Article  PubMed  Google Scholar 

  67. Eichenauer DA, Engert A, Dreyling M, ESMO Guidelines Working Group. Hodgkin’s lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22 Suppl 6:vi55–8.

    PubMed  Google Scholar 

  68. Gobbi PG, Ferreri AJ, Ponzoni M, Levis A. Hodgkin lymphoma. Crit Rev Oncol Hematol. 2013;85(2):216–37.

    Article  PubMed  Google Scholar 

  69. Hartridge-Lambert SK, Stein EM, Markowitz AJ, Portlock CS. Hepatitis C and non-Hodgkin lymphoma: the clinical perspective. Hepatology. 2012;55(2):634–41.

    Article  PubMed  Google Scholar 

  70. Weidmann E. Hepatosplenic T cell lymphoma. A review on 45 cases since the first report describing the disease as a distinct lymphoma entity in 1990. Leukemia. 2000;14(6):991–7.

    Article  CAS  PubMed  Google Scholar 

  71. Visnyei K, Grossbard ML, Shapira I. Hepatosplenic gammadelta T-cell lymphoma: an overview. Clin Lymphoma Myeloma Leuk. 2013;13(4):360–9.

    Article  CAS  PubMed  Google Scholar 

  72. Kotlyar DS, Osterman MT, Diamond RH, Porter D, Blonski WC, Wasik M, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011;9(1):36–41.e1.

    Article  CAS  PubMed  Google Scholar 

  73. Subramaniam K, Yeung D, Grimpen F, Joseph J, Fay K, Buckland M, et al. Hepatosplenic T-cell lymphoma, immunosuppressive agents and biologicals: what are the risks? Intern Med J. 2014;44(3):287–90.

    Article  CAS  PubMed  Google Scholar 

  74. Morgan RL, Baack B, Smith BD, Yartel A, Pitasi M, Falck-Ytter Y. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med. 2013;158(5 Pt 1):329–37.

    Article  PubMed  Google Scholar 

  75. van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308(24):2584–93.

    Article  PubMed  Google Scholar 

  76. Altekruse SF, Henley SJ, Cucinelli JE, McGlynn KA. Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. Am J Gastroenterol. 2014;109(4):542–53.

    Article  PubMed  PubMed Central  Google Scholar 

  77. Njei B, Rotman Y, Ditah I, Lim JK. Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology. 2015;61(1):191–9.

    Article  PubMed  Google Scholar 

  78. Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol. 2013;10(11):656–65.

    Article  CAS  PubMed  Google Scholar 

  79. White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol. 2012;10(12):1342–1359.e2.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

Financial Support/Disclosure: No external funding was used for this study. No authors report conflicts of interest.

Author information

Authors and Affiliations

  1. Division of Gastroenterology and Hepatology, Department of Medicine, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, L-461, Portland, OR, 97239, USA

    Michael Loudin M.D. & Barry Schlansky M.D., M.P.H.

  2. Austin Outpatient Clinic, Central Texas Veterans Health Care System, 7901 Metropolis Drive, Austin, TX, 78744, USA

    Ranjan Mascarenhas M.D.

Authors
  1. Michael Loudin M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ranjan Mascarenhas M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Barry Schlansky M.D., M.P.H.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Barry Schlansky M.D., M.P.H. .

Editor information

Editors and Affiliations

  1. Division of Gastroenterology and Hepatology, Medical College of Wisconsin , Milwaukee, Wisconsin, USA

    Kia Saeian

  2. Division of Gastroenterology and Hepatology, Medicine Medical College of Wisconsin , Milwaukee, Wisconsin, USA

    Reza Shaker

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Loudin, M., Mascarenhas, R., Schlansky, B. (2017). Malignant Liver Lesions. In: Saeian, K., Shaker, R. (eds) Liver Disorders. Springer, Cham. https://doi.org/10.1007/978-3-319-30103-7_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-30103-7_6

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-30101-3

  • Online ISBN: 978-3-319-30103-7

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation